"Our Pursuit, Life’s Potential." That is Allergan’s vision, and every day, around the globe, our more than 11,000 employees work to deliver on this vision.

A lot of healthcare companies talk about patients’ "unmet needs." They use that phrase so often, in fact, that it just becomes a buzz-phrase with no real meaning. Our employees’ dedication drives us to understand what underlies the needs of patients, as well as the physicians who treat those patients. Their dedication leads to the discovery and development of products that not only target what the patient physically requires, but also allows them to expand their own potential.

Through this Web site, we will highlight what makes Allergan a different kind of company: a unique combination of biotechnology, pharmaceuticals and medical device manufacturing, that avoids bureaucracy in favor of efficient and fast decision-making. We will also take a broader view, looking at important trends in healthcare and business. Among other features, the site will include a new blog. In this blog, I will write about topics that relate to Allergan and our employees, as well as those that impact the world at large – ranging from the impact of health reform on innovation, to trends in targeted therapies, to the responsibilities of businesses for sustainable practices and growth.

I invite you to visit the site regularly. We may tweak some noses along the way, but we will always call it as we see it.


David E.I. Pyott, CBE
Chairman of the Board and Chief Executive Officer

Twitter And Blog Feed

The U.S. corporate tax code is certainly in need of reform as we have the highest corporate tax rate of the major countries in the world. Everyone knows this, and it may ... read more
Of the myriad pieces to the healthcare puzzle in the U.S., perhaps the most important are the providers of healthcare, including physicians. One element of healthcare... read more
The JP Morgan Healthcare Conference - the largest annual gathering of the healthcare industry and the investment community - has, without doubt, grown over the years. In ... read more
In looking at 2014 for the pharmaceutical industry, it pays to look at our recent past. Much of the last two years has been about moving through the well-documented... read more
While the Medical Device tax has earned a lot of attention this year in the United States, there has also been buzz around the European Union’s new approval system for... read more
With 2,500-plus pages of legislation and 12,000 pages (and counting) of subsequent regulatory language, the Affordable Care Act (ACA) was bound to have some surprises in ... read more
"Big Data" - the analysis of large and complex bodies of data which allows greater correlation of information and identification of trends – has been in the headlines a... read more
Looking for a few billion dollars in savings on healthcare costs in the U.S.? According to a new study from the IMS Institute for Healthcare Informatics, improved... read more
The tide of counterfeit and illegally imported drugs and medical devices continues to be strong, as difficult economic times drives demand for seemingly cheaper... read more
For a long time, the manufacturing process for pharmaceuticals and biologics has been a largely overlooked aspect in drug development. This is changing, and in my view,... read more
Earlier this year, the publication Corporate Counsel published a survey of Intellectual Property (IP) counsels in the pharmaceutical and biotech sectors reporting that... read more
At the recent BIO Convention, Ernst & Young issued its annual biotechnology industry report Beyond Borders: Matters of Evidence. The report featured a survey of biotech... read more
This year's Biotechnology Industry Organization (BIO) convention served, as it so often does, as a bit of a "barometer" of how the industry is faring. As an attendee and ... read more
In my last post, I discussed some "macro" Affordable Care Act (ACA) issues impacting the pharmaceutical industry one year after the Supreme Court ruling. Yet for the... read more
A year ago, the U.S. Supreme Court ruled on the constitutionality of key parts of the Patient Protection and Affordable Care Act of 2010 ("ACA"). During that time, many... read more
One of the realities of federal laws in the United States is that the passage of legislation is not an end point, but merely a step in what can be a lengthy process as... read more
Early this year, the chairman of the Pharmaceutical Research and Manufacturing Association (PhRMA) announced the principal results of a report on the industry's pipeline ... read more
Medical devices are an often-overlooked sector of the health care industry, but with their contribution to innovation and the economy in general, there should be much... read more
In the pharmaceutical industry, companies talk a lot about being "patient-centric." But what does it mean to be "patient-centric?" Is it about how patients view a... read more
After the rollercoaster ride of 2012 - the drama around the Supreme Court ruling on the Affordable Care Act, the U.S. presidential election, economic concerns in the... read more
Only a couple of years ago, we were frequently reading about the pharmaceutical industry's "gold rush" mentality regarding emerging markets. During this time, companies... read more
It's no secret that developing new drugs demands significant and increasing resources, both in time and money. New drug development can take a decade or more, at a cost... read more
Whether seen through the mixed results from the corporate earnings reporting "season" for the second quarter of 2012 or the ongoing news coverage, it is clear Europe's... read more
Just a couple weeks ago, Allergan was commended, for the fifth consecutive year, by the Carbon Disclosure Project (CDP) for our actions in reducing emissions and... read more
The Prescription Drug User Fee Act (PDUFA) was signed into law in 1992 authorizing FDA to collect fees from companies that produce human drugs and biologics, with these... read more
Unless you've been on a long vacation to a remote location or stayed completely away from newspapers, television, radio, and the Internet, chances are that you've heard... read more
During my time at the recent BIO International Conference (the world's largest biotech event, sponsored by the Biotechnology Industry Organization) in Boston, two... read more
Whether you love, hate or are indifferent to the Patient Protection and Affordable Care Act (PPACA), everyone can agree that it's one of the most far-reaching laws ever... read more
Big Pharma has shown a lot of activity over the years – and recently it appears that Big Pharma is on the move again. A few years ago, mergers of large... read more
Most companies that provide a good or service widely profess "our customers are our highest priority." That's no surprise; without customers, you can't be in business.... read more
A continuing theme in the world of Big Pharma is "what will the industry do about its pipeline?" As blockbuster pharmaceutical products come to the expiry of their... read more
Apple recently took a swipe at U.S. tax policy, and it made news. At issue was how the company would use its $100 billion cash in hand. We learned that at least one... read more
The Patient Protection and Affordable Care Act of 2010 (or PPACA) has now been around for more than two years, and still generates a lot of attention. Whether from the... read more
As I go to industry events and have a chance to meet with colleagues from other companies in the pharmaceutical and biological industry, I occasionally hear comments... read more
Much of the attention of late to the healthcare reform legislation known as the Patient Protection and Affordable Care Act of 2010 (frequently short-handed as the... read more
Being a global company, we tend to look at things from a broad perspective, but it's hard to ignore the stagnation that the U.S. economy has settled into. There are some ... read more
The U.S. economy is growing at a snail's pace. Europe's economy limps along. Governments throughout the "developed" world contend with debilitating budget deficits. Is... read more
How often do you hear from companies and organizations some variation on the phrase: "People are our most important resource?" It's said so often, it's almost become a... read more
Recently I participated in some investor research conducted by UBS involving 14 CEOs from top specialty pharmaceutical companies, giving a perspective on where the... read more
In September, I spoke with a reporter from Reuters, the global news service. The article that came out of that conversation was mostly about the size of Botox in... read more
INowadays, the poor state of the economy and tight government budgets are a constant refrain in the media. The cost of healthcare is a persistent part; in the United... read more
With Western economies stuck in the doldrums for the past several years, a lot of attention has shifted to China's economic growth and its potential as a new market. The ... read more